Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Alison Oliveto to Buprenorphine

This is a "connection" page, showing publications Alison Oliveto has written about Buprenorphine.

 
Connection Strength
  
 
 
1.181
  
  1. Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302.
    View in: PubMed
    Score: 0.386
  2. Tsai PF, Oliveto AH, Landes RD, Mancino MJ. Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice. J Opioid Manag. 2023 Jul-Aug; 19(4):329-341.
    View in: PubMed
    Score: 0.192
  3. Gokarakonda SB, Boydstun JM, Yilanli M, Han X, Kumar N, Oliveto AH, Mancino MJ. Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2022 05; 31(3):219-225.
    View in: PubMed
    Score: 0.175
  4. Phillips SJ, Oliveto A, Mancino MJ, Hendrickson HP. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum. Rapid Commun Mass Spectrom. 2021 Jul 31; 35(14):e9104.
    View in: PubMed
    Score: 0.168
  5. Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17.
    View in: PubMed
    Score: 0.053
  6. Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004 Mar-Apr; 13(2):191-201.
    View in: PubMed
    Score: 0.050
  7. Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514.
    View in: PubMed
    Score: 0.048
  8. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003 Jun 05; 70(3):315-25.
    View in: PubMed
    Score: 0.048
  9. Kosten T, Poling J, Oliveto A. Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction. 2003 May; 98(5):665-71.
    View in: PubMed
    Score: 0.048
  10. Feingold A, Oliveto A, Schottenfeld R, Kosten TR. Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict. 2002; 11(2):111-23.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.